Nastech Pharmaceutical Company (MM) (NASDAQ:NSTK)
Historical Stock Chart
From Jan 2020 to Jan 2025
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that
its first quarter financial results will be released on Thursday, May 8,
2008, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time). Management
will then host a conference call beginning at 4:30 p.m. Eastern Time
(1:30 p.m. Pacific Time) to discuss first quarter financial results and
provide a corporate update.
To participate in the live conference call, U.S. residents should dial
800-638-5439 and international callers should dial 617-614-3945. The
passcode for the live conference call is 67443467. To access the 24-hour
telephone replay, U.S. residents should dial 888-286-8010 and
international callers should dial 617-801-6888. The passcode for the
replay is 97916996.
Alternatively, to access the live audio webcast for this conference call
or the subsequent 30-day archive, please log on to Nastech’s
Web site at http://www.nastech.com
approximately 15 minutes prior to the conference call in order to
register and download any necessary software.
About Nastech
Nastech is a clinical stage biopharmaceutical company focusing on the
development and commercialization of innovative therapeutic products
based on its proprietary ribonucleic acid interference technology and
proprietary molecular biology-based drug delivery technologies. Nastech
and its collaboration partners are developing products for multiple
therapeutic areas including diabetes, obesity, osteoporosis, autism,
respiratory diseases and inflammatory conditions. Additional information
about Nastech is available at http://www.nastech.com.
Nastech Forward-Looking Statements
Statements made in this news release may be forward-looking statements
within the meaning of Federal Securities laws that are subject to
certain risks and uncertainties and involve factors that may cause
actual results to differ materially from those projected or suggested.
Factors that could cause actual results to differ materially from those
in forward-looking statements include, but are not limited to: (i) the
ability of Nastech or a subsidiary to obtain additional funding; (ii)
the ability of Nastech or a subsidiary to attract and/or maintain
manufacturing, research, development and commercialization partners;
(iii) the ability of Nastech, a subsidiary and/or a partner to
successfully complete product research and development, including
preclinical and clinical studies and commercialization; (iv) the ability
of Nastech, a subsidiary and/or a partner to obtain required
governmental approvals; and (v) the ability of Nastech, a subsidiary
and/or a partner to develop and commercialize products that can compete
favorably with those of competitors. Additional factors that could cause
actual results to differ materially from those projected or suggested in
any forward-looking statements are contained in Nastech's most recent
periodic reports on Form 10-K and Form 10-Q that are filed with the
Securities and Exchange Commission. Nastech assumes no obligation to
update and supplement forward-looking statements because of subsequent
events.